.jpg?w=340&itok=JMebVBMQ "EPR in healthcare news."){kind=icon}
Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
The power of partnership: Collaborating with patient advocacy organisations for better clinical research
Laura Iliescu explores the powerful potential of collaboration with PAOs for clinical trials, particularly how PAOs can inform trial design and the creation of patient registries.
-
Inclusive approaches to diversity and inclusion
Devra Densmore, Senior Lead of Patient Advocacy Strategy at the Centre for Rare Diseases at ICON, discusses the importance of DEI in rare disease clinical trials and shares actionable points for a more inclusive approach.
-
Rare disease drug development
In this article, Will Maier outlines the importance of utilising real world evidence from rare diseases in accelerating product approval and development.
-
.jpg?w=545&itok=0y12uiTd "EPR in healthcare news.")
Using RWE in rare disease drug development: effective innovations with historical controls
With a growing number of therapies under development for rare diseases, William Maier discusses how real-world evidence can be effectively used as a historical control, overcoming challenges presented in clinical development.
-
How real world evidence is impacting rare disease drug development
Will Maier, VP of Rare Diseases, shares how a more patient-focused approach to trials is leading to alternatives for randomisation.
-
Real world evidence and the patient experience: Involving rare disease patients for successful trials
ICON's William C Maier and Maggie Adamski discuss case studies from their line of work, and how real world evidence can support those suffering with rare diseases around the world.
-
An overview on rare disease research
ICON's Tim Clark and Will Maier examine the key clinical, regulatory, and commercial challenges associated with the development of therapies for the treatment of rare diseases.
